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2ABSTRACT 
The transcription factor Bcl6 is a master regulator of follicular helper T (TFH) cells, and 
understanding the signaling pathway that induces Bcl6 and TFH cell differentiation is therefore 
critical. IL-2 produced during T cell activation inhibits Bcl6 expression but how TFH cells evade IL-
2 inhibition is not completely understood. Here we show that Bcl6 is highly up-regulated in 
activated CD4 T cells following glucose deprivation (GD), and this pathway is insensitive to 
inhibition by IL-2. Similar to GD, the glucose analog 2-deoxyglucose (2DG) inhibits glycolysis, and 
2DG induced Bcl6 expression in activated CD4 T cells. The metabolic sensor AMP kinase (AMPK) 
is activated when glycolysis is decreased, and the induction of Bcl6 by GD was inhibited by the 
AMPK antagonist compound C. Additionally, activation of AMPK by the drug AICAR caused Bcl6 
up-regulation in activated CD4 T cells. When mice were immunized with KLH using AICAR as an 
adjuvant, there was a strong TFH–dependent enhancement of KLH-specific antibody (Ab) 
responses, and higher Bcl6 expression in TFH cells in vivo. Activation of AMPK strongly induced 
BCL6 and the up-regulation of TFH cell marker expression by human CD4 T cells. Our data reveal 
a major new pathway for TFH cell differentiation, conserved by both mouse and human T cells. 
Mature TFH cells are reported to have a lower metabolic state compared to TH1 cells. Our data 
indicates that decreased metabolism may be deterministic for TFH cell differentiation, and not 
simply a result of TFH cell differentiation.  
1. Introduction
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Follicular T helper (TFH) cells help B cells form germinal centers (GCs) and produce high-
affinity antibodies (Abs) (Fazilleau et al. 2009; Crotty et al. 2010). TFH cells control the initiation 
as well as the outcome of the GCB cell response (Breitfeld et al. 2000; Schaerli et al. 2000; 
Vinuesa et al. 2005; McHeyzer-Williams et al. 2009). Thus, TFH cells are critical for the proper 
production of protective Abs during an infection. However the over-production of TFH cells can 
also lead to autoimmunity, since excess TFH cell activity can help self-reactive B cells to produce 
auto-Abs (Vinuesa et al. 2005; Odegard et al. 2008; Linterman et al. 2009). Understanding the 
proper regulation of TFH cell differentiation is essential for devising strategies that either promote 
beneficial Ab responses or prevent Ab-mediated autoimmune diseases.  
Bcl6 is a transcriptional repressor that is essential for the development and stability of 
TFH cells (Johnston et al. 2009; Nurieva et al. 2009; Yu et al. 2009; Crotty 2011; Hollister et al. 
2013). How Bcl6 expression is induced to promote TFH cell differentiation has been the subject 
of much interest, and can be driven by STAT factor transcription following signaling by cytokines 
such as IL-6 and IL-12 (Poholek et al. 2010; Crotty 2011; Schmitt et al. 2014). The stable 
activation of Bcl6 expression in CD4 T cells during TFH cell differentiation has to overcome two 
critical impediments: 1) Bcl6 strongly auto-represses its own expression (Pasqualucci et al. 
2003; Mendez et al. 2008), and 2) IL-2 produced during T cell activation inhibits Bcl6 expression 
(Ballesteros-Tato et al. 2012; Johnston et al. 2012; Nurieva et al. 2012; Oestreich et al. 2012; 
Liao et al. 2014). TFH-like cells can be generated in vitro with human CD4 T cells and 
STAT3/STAT4-activating cytokines plus TGF (Schmitt et al. 2014). However, these same 
signals do not promote mouse TFH cell differentiation in vitro, and in particular, TGF plays 
different roles in mouse versus human CD4 T cell differentiation (Schmitt et al. 2014). Recently, 
Cyster and colleagues found that during an immune response, dendritic cells (DCs) can up-
regulate expression of the IL2 receptor (IL2R) in order to compete with IL-2 signaling by CD4 T 
cells and this promotes TFH cell differentiation (Li et al. 2016). While this DC-IL2R mechanism 
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appears to be important for early TFH cell differentiation, much work remains to understand the 
relevance of this pathway in different immune settings. Another mechanism for blocking IL-2 in 
vivo to promote TFH cell differentiation involves IL2R-expressing regulatory T (Treg) cells (Leon 
et al. 2014). The significance of this pathway in different immune settings is also unclear.  
Another potential pathway for controlling IL-2 during the T cell response is through glycolysis, 
since decreased glycolysis leads to decreased IL-2 translation (Chang et al. 2013). 
Because of the complexity of Bcl6 regulation as noted above, the potential for regulation 
of IL-2 expression via glycolysis (Chang et al. 2013) and the fact that TFH cells have an unusual 
state of low metabolism for effector T cells (Ray et al. 2015), we pursued the idea that Bcl6 
expression and TFH cell differentiation is uniquely controlled by metabolic signals. We now report 
a pathway for the regulation of Bcl6 controlled by the metabolic sensor AMPK. This pathway 
overrides, or is downstream of, the inhibitory effect of IL-2 on Bcl6 expression. Our new data 
indicate that metabolic cues during T cell activation can determine whether an activated CD4 T 
cell can become a TFH cell versus another type of effector T helper cell. Importantly, the AMPK-
BCL6 pathway is shared by mouse and human CD4 T cells, revealing a new evolutionarily 
conserved pathway for TFH cell differentiation. 
52. Results
Bcl6 is regulated by glycolysis. Since blocking glycolysis during T cell activation 
results in an inhibition of cytokine mRNA translation, such that secretion of IFN and IL-2 is 
markedly decreased (Chang et al. 2013), we reasoned that blocking glycolysis might play a role 
during TFH differentiation, by blocking inhibitory IL-2. Initially, as in Chang et al (Chang et al. 
2013), we activated wild-type (WT) naïve CD4 T cells in glucose versus galactose medium, but 
we did not observe significant differences in Bcl6 expression (data not shown). However, as a 
control, we also activated naïve CD4 T cells in medium without added glucose or galactose, and 
analyzed Bcl6 mRNA expression by QPCR. As shown in Figure 1A, compared to T cells 
activated in 25 mM glucose, Bcl6 was increased over 20-fold when the T cells were activated in 
the absence of added glucose. This was accompanied by an up-regulation of Bcl6 protein, as 
measured by intracellular staining and flow cytometry (Fig. 1B). We tested if a transformed T 
cell line showed this same regulation of Bcl6 by glucose withdrawal, and so we tested the EL4 
lymphoma cell line by culturing the cells with glucose or without glucose. We observed a similar 
high increase in Bcl6 mRNA after 48 h in glucose-deprived conditions, and protein was 
increased as well as analyzed by flow cytometry (Fig. 1 C, D). Using Cell Trace Violet (CTV)-
labeling, we found that Bcl6 was preferentially increased in the no glucose condition compared 
to the glucose added condition, although there was significantly less cell division without 
glucose (Suppl. Fig. 1). We then tested the effect of the non-metabolizable glucose analogue 2-
deoxyglucose (2DG) when it was added to naïve CD4 T cells activated in DMEM medium 
containing glucose. As shown in Figure 1E, Bcl6 mRNA increased over 4-fold when metabolism 
of the normal glucose in the culture is inhibited by 2DG.  Because the effect of complete glucose 
deprivation (GD) on Bcl6 induction was much stronger than the effect with 2DG, we chose to 
focus on GD for further studies. Note, our medium contains glutamine that can be used as an 
alternative energy source for T cells (Wang et al. 2011; Blagih et al. 2015), though there is 
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increased cell death and decreased proliferation in the absence of glucose. We wondered if 
glucose withdrawal was inhibiting T cell activation, therefore we analyzed IL-2 (Il2) and IL-2 
receptor alpha (Il2ra) chain gene expression. As shown in Figure 2, in the absence of glucose, 
naïve CD4 T cells still become activated to transcribe levels of Il2 and Il2ra mRNAs comparable 
to with glucose conditions. However, consistent with published findings that inhibition of 
glycolysis leads to a block in cytokine translation (Chang et al. 2013), IL-2 was secreted at 
significantly lower levels in T cells activated under GD conditions than under plus glucose 
conditions (Fig. 2C). Nonetheless, substantial levels of IL-2 were still secreted under GD 
conditions (Fig. 2C).  
Regulation of Bcl6 by glucose is largely independent from inhibition by IL-2. We 
wondered if the decreased IL-2 in the GD conditions was leading to the increased Bcl6 levels. 
We then tested whether adding exogenous IL-2 could down-regulate the induction of Bcl6 in T 
cells seen with GD, by supplementing the GD cultures with high levels of recombinant human 
IL-2. However, the added IL-2 had no effect on Bcl6 (Fig. 3A). Since it is difficult to determine if 
the added human IL-2 was added to an inhibitory level equivalent to that made by T cells in Glu 
added conditions, we sought another approach to test this question. In order to stringently test 
the role of IL-2 in the GD effect on Bcl6, we used T cells from IL-2-deficient (KO) mice. When 
activated in vitro, IL-2 KO T cells have a higher level of Bcl6 expression than WT T cells, likely 
due to their inability to produce IL-2 (data not shown). We then activated naïve CD4 T cells from 
IL-2KO mice in plus glucose or GD conditions (Fig. 3B). When IL-2 was added to the IL-2 KO T 
cells activated in plus glucose conditions, Bcl6 was sharply decreased, whereas addition of a 
similar amount of IL-2 to IL-2 KO T cells activated in GD conditions did not significantly 
decrease Bcl6 expression (Fig. 3B). These data indicate that the activating effect of GD on Bcl6 
expression is dominant over the inhibition by IL-2.  
Up-regulation of Bcl6 by glucose deprivation can occur in a secondary stimulation 
setting. One pitfall of Bcl6 induction by GD is that lack of glucose during T cell activation 
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prevents the strong T cell expansion that normally occurs during antigen stimulation in vivo. We 
therefore wondered if we could induce Bcl6 by GD in a secondary stimulation, after an initial 
stimulation and expansion in glucose-containing media. We thus conducted an experiment 
where naïve CD4 T cells were activated in plus glucose media, and then after 2 days, collected, 
washed, and re-activated under either plus glucose or GD conditions. As shown in Figure 4A, 
Bcl6 transcript is strongly induced in secondary stimulation under GD conditions. The transcript 
for the activation/TFH marker PD-1 (Pdcd1) was strongly up-regulated under GD conditions 
along with Bcl6 (Fig. 4B), and the key TFH marker Cxcr5 was also increased in GD conditions 
compared to plus glucose (data not shown). Notably, the transcript for Blimp-1 (Prdm1) was not 
markedly increased (Fig. 4C), showing specificity for the GD effect. We then stained cells 
cultured in the secondary stimulation condition for Bcl6 (Fig. 4D, E), Tbet (Fig. 4F) and Foxp3 
(Fig. 4G), and found that only Bcl6 was increased following GD. This data shows that key parts 
of the TFH cell profile (Bcl6 and PD-1) can be induced during an ongoing T cell response, if 
glucose in the immune environment is depleted while T cells are still being stimulated through 
the TCR. These results therefore indicate a novel, metabolically-regulated pathway for TFH cell 
differentiation during the immune response.  
Bcl6 and the TFH response is regulated by AMP kinase. Next, we wanted to explore 
the signaling pathway that leads to induction of Bcl6 expression after GD. The major metabolic 
sensor for GD is AMP kinase (AMPK), which is activated by elevated AMP levels (Carling 2004; 
Hardie 2007). Several drugs have been developed that target AMPK, compound C is a small 
molecule inhibitor of AMPK activity, and the AMP analog AICAR activates AMPK (Zhou et al. 
2001; Vincent et al. 2015). We thus tested the activity of AMPK in regulating Bcl6 expression 
using these drugs. As shown in Figure 5A, naïve CD4 T cells secondarily activated under GD 
conditions induce strong Bcl6 expression as expected, but this up-regulation of Bcl6 can be 
reversed by compound C treatment. Furthermore, AICAR stimulates significant Bcl6 expression 
in naïve CD4 T cells secondarily activated (Fig. 5B) in the presence of glucose. AICAR 
8stimulation was also able to induce higher Bcl6 expression under “TFH” culture conditions that 
block IL-2 and increase the expression of Bcl6 and TFH markers such as Cxcr5 and Pdcd1. 
Taken together, these data indicate that AMPK has key role in Bcl6 regulation in CD4 T cells 
and may play a role in induction of the TFH phenotype. Previously, AMPK was shown to 
positively regulate BCL6 transcription in human endothelial cells, by a mechanism involving 
inactivation of PARP1 (Gongol et al. 2013). To our knowledge, the data here is the first data 
linking Bcl6 and AMPK in T cells. Previously, it was shown that AICAR could act as an adjuvant 
in mice to enhance Ab responses, however TFH cell responses were not specifically analyzed in 
this study (Andris et al. 2011). We therefore repeated this experiment, by injecting mice with the 
antigen Keyhole Limpet Hemocyanin (KLH) either with or without AICAR. As shown in Figure 
6A, in wild-type (WT) mice, AICAR significantly enhanced the anti-KLH IgG titer by about 3-fold. 
We then tested if this Ab response was driven by TFH cells, using T cell specific Bcl6 cKO mice 
(Hollister et al. 2013). Loss of Bcl6 in T cells completely ablates development of TFH cells and 
GC B cells. When cKO mice were immunized, the overall Ab response was lower due to lack of 
a GC B cell response, and AICAR did not boost the Ab response to any degree (Fig 6A). These 
data indicate that AICAR specifically enhances the TFH cell-dependent Ab response. To more 
carefully analyze if AICAR affected TFH cells, we analyzed responding T cells in immunized mice 
at days 3, 7 and 14 after immunization with KLH or KLH plus AICAR. However, AICAR did not 
significantly enhance the frequency or number of TFH cells induced by immunization (Fig. 6B 
and data not shown), although the percentage of TFH cells was slightly higher following AICAR. 
However, we did observe that within the TFH cells, Bcl6 expression was significantly enhanced 
by AICAR (Figure 6C). This data is consistent with our in vitro work showing that AICAR can 
enhance BCL6 expression. Additionally, AICAR significantly increased the number of GC B cells 
(Fig. 6D), which may be the result of more potent TFH cell activity due to higher Bcl6 expression, 
or due to a separate effect of AICAR on B cells. 
9AMPK regulates BCL6 and TFH markers in human T cells. Since conditions for TFH 
cell differentiation have been more clearly characterized in human T cells compared to mice 
(Schmitt et al. 2014), we were curious if our findings with regulation of mouse Bcl6 by AMPK 
translated to human T cells. We therefore isolated naïve CD4 T cells from human peripheral 
blood mononuclear cells (PBMC), stimulated them in vitro with anti-CD3/anti-CD28 beads, and 
added reagents that modulate AMPK activity. We found that 2DG potently up-regulated both 
BCL6 and CXCR5 in human CD4 T cells (Fig. 7A, B). In fact human T cells were extremely 
sensitive to 2DG compared to mouse cells, such that only 1.25 mM 2DG was effective at 
increasing BCL6, whereas much higher concentrations of 2DG were required to induce Bcl6 in 
mouse T cells (Fig. 1E). Nonetheless, this result indicated a similar regulatory pathway might 
exist for both mouse and human T cells. We then tested AICAR in the human CD4 T cell culture 
system. Similar to what we observed in mouse T cells, AICAR was effective at significantly 
inducing BCL6 expression, both at the mRNA (Fig. 7C) and protein (Fig. 7D) level. Unlike with 
mouse T cells, AICAR induced significant up-regulation of the TFH markers CXCR5 (Fig. 7E) and 
PD-1 (Fig. 7F). Strikingly, AICAR was more effective at inducing transcription of BCL6 (Fig. 7C) 
and CXCR5 (Fig. 7E) than when the CD4 T cells were cultured in characterized TFH cell 
conditions (Schmitt et al. 2014).  These data indicate that mouse and human T cells share a 
common AMPK pathway for inducing BCL6, however it also appears that human CD4 T cells 
are also more prone to develop into TFH–like cells than mouse CD4 T cells when this pathway is 
activated.  
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3. Discussion  
 
TFH cells orchestrate the germinal center reaction and hence control the production of high 
affinity antibodies to antigen, yet the pathways for how TFH cells develop are not well understood 
either in vivo or in vitro. Here we have uncovered a novel mode of inducing the master TFH cell 
regulator Bcl6 involving the metabolic sensor AMPK. Our work here follows a great deal of recent 
work showing that effector T cell responses are promoted by glycolysis and AMPK (Wang et al. 
2011; Chang et al. 2013; Sukumar et al. 2013; Blagih et al. 2015), however TFH cell responses 
were not analyzed in these previous studies. Our findings here add a new twist to the metabolic 
regulation of T cells, and indicate that inhibition of glycolysis, with the resulting activation of AMPK, 
induces Bcl6 expression, which can promote TFH cell responses. Although previous studies have 
shown that Bcl6 is positively regulated by AMPK in endothelial cells (Gongol et al. 2013), and that 
Bcl6 is up-regulated by glucose deprivation (GD) in pancreatic cancer cells (Glauser and Schlegel 
2009), our findings here shows that this pathway is operational in CD4 T cells, both in mouse and 
human, and that this pathway can impact TFH cell differentiation. 
Curiously, TFH cells have a unique metabolic profile, with a dampened metabolism 
compared to other effector T cells (Ray et al. 2015). This decreased metabolism may be due in 
part because Bcl6 is able to repress genes in the glycolysis pathway (Oestreich et al. 2014). Thus, 
if Bcl6 suppresses glycolysis, TFH cells should have strongly suppressed glycolysis due to their 
high expression level of Bcl6. A major unresolved question is how this dampened metabolism 
contributes to the function of TFH cells. In the GC, B cells present cognate Ag to TFH cells and 
stimulate the TFH cells through the TCR to allow for elaboration of helper cytokines. TFH cells need 
to be specifically activated in order to help GC B cells, and it has been proposed that strict control 
of cytokine secretion by TFH cells is a key aspect of their function (Havenar-Daughton et al. 2016; 
Wu et al. 2016). How cytokine expression is controlled in TFH cells following interaction with GC 
B cells presenting cognate Ag is a particularly important question for understanding B cell 
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selection in the GC. We propose that metabolism is normally dampened in TFH cells specifically 
to limit the non-specific secretion of cytokines by TFH cells in the GC, and that metabolism is 
transiently activated in TFH cells that are stimulated by cognate GC B cells. Whether the glucose 
concentration in the GC micro-environment influences this sort of on-off regulation of TFH cell 
metabolism is an interesting question that warrants further study. 
Previous studies have found that Bcl6 is induced by AMPK in endothelial cells (Gongol et 
al. 2013), and that Bcl6 is up-regulated following glucose deprivation (GD) in pancreatic cancer 
cells (Glauser and Schlegel 2009), these studies presented different mechanisms for how Bcl6 is 
induced. In the endothelial cell study, AMPK was shown to inactivate PARP1, which normally 
represses BCL6 (Gongol et al. 2013), and thus AMPK signaling relieves repression on BCL6. In 
the glucose deprivation study, activated Foxo1 was shown to induce Bcl6 expression (Glauser 
and Schlegel 2009). We showed many years ago that Foxo4 positively regulates Bcl6 (Tang et 
al. 2002), and AMPK can regulate multiple Foxo factors (Nystrom and Lang 2008). Interestingly, 
Foxo1 was shown to repress early TFH cell differentiation, but also was required for maximal Bcl6 
expression and full TFH cell differentiation (Stone et al. 2015). Overall, it is likely that the regulatory 
pathway for how AMPK activates BCL6 is complex and involves several downstream transcription 
factors that respond to metabolic signals. While Foxo factors are well-known for responding to 
metabolic signals and for regulating metabolism, PARP-1 is also responsive to the metabolic state 
of the cell, as it utilizes the metabolic product NAD+ for its enzymatic function (Luo and Kraus 
2012). 
Although we found Bcl6 was strongly induced when glycolysis was inhibited, inhibition of 
glycolysis is also detrimental to T cell activation and proliferation (Wang et al. 2011; Chang et al. 
2013; Sukumar et al. 2013; Blagih et al. 2015; Yin et al. 2015; Yin et al. 2016; Zeng et al. 2016). 
Thus, during a strong T cell proliferative response, abundant glucose is required, and it is unlikely 
that Bcl6 will be activated by low energy signals through AMPK during a highly proliferative T cell 
response. Furthermore AMPK appears to be inhibitory to TFH cell responses (Ramiscal et al. 
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2015). However, we think it is critical to distinguish early T cell activation and expansion from TFH 
cell differentiation that occurs later in the response. We hypothesize that during a strong T cell 
response, glucose can be depleted locally, and this can lead to Bcl6 activation via AMP activated 
AMPK. Indeed, we showed that Bcl6 was induced by glucose deprivation, following an initial T 
cell activation in the presence of glucose (Figure 4). Although it remains to be tested in vivo, this 
is a plausible pathway for the development of TFH cells during an active immune response, and 
critically, it is a way for TFH cells to develop in the presence of inhibitory IL-2. Thus, experiments 
using different types of cKO mice where glucose metabolism is inhibited during T cell activation 
may give misleading results about the effect of TFH cell responses, when really the effect is on 
early T cell activation. Similarly cKO mice for AMPK may show augmented TFH cell responses 
because early T cell activation is increased due to loss of inhibitory activity of AMPK at that stage 
(Ramiscal et al. 2015). 
The fact that Bcl6 represses glycolysis (Oestreich et al. 2014), makes the activation of 
Bcl6 transcription by glucose deprivation, where glycolysis cannot occur, remarkable. This 
expression pathway indicates that Bcl6 may be part of an important feedback loop used by the 
cell to shut off glycolysis, which uses glucose, when glucose is in short supply. This potential 
regulatory circuit is highly novel and will be pursued in future research. Whether induction of Bcl6 
by AMPK has different effects on glycolysis in glucose deprivation conditions versus when 
glucose is present is another important issue for future investigation.   
Ultimately, these findings have significant therapeutic potential, since targeting AMPK by 
pharmaceutical agents can be used for augmenting TFH cells during vaccination, or for inhibiting 
TFH cells in an auto-immune disease setting. 
4. Materials and Methods
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Mice and immunizations. C57BL/6J mice were obtained from Jackson labs and then bred in 
house. Bcl6fl/fl mice (Hollister et al. 2013) were backcrossed to CD4-cre transgenic mice (Lee et 
al. 2001) and the C57BL/6 strain for at least six generations. IL-2 knockout mice were obtained 
from Jackson labs. Mice were bred under specific pathogen-free conditions at the laboratory 
animal facility at Indiana University School of Medicine and were handled according to protocols 
approved by the Indiana University School of Medicine Institutional Animal Use and Care 
Committee (IACUC). For NP-KLH immunization, mice were intraperitoneally (i.p.) injected with 
100 μg NP (27) -KLH (Biosearch Technologies) and were sacrificed at the indicated day. For 
AICAR NP-KLH immunization, 5-10 mg AICAR (Sigma-Aldrich) was mixed with 100 μg NP (27) 
–KLH in PBS and the mixture was injected i.p., similarly to Andris et al (Andris et al. 2011). 
 
Mouse T cell culture. Naïve CD4 T cells were isolated from the spleen via isolation kit (Miltenyi 
Biotec). Cells were activated with plate-bound anti-CD3 (10 μg/ml; 145-2C11; Bio X Cell) and anti-
CD28 (10 μg/ml; 37.51; Bio X Cell) for 72 h in culture medium, at 1 X 106 cells/ml. Glucose-free 
culture medium was glucose-free DMEM media (Gibco/LifeTechnologies) supplemented with 
10% dialyzed FBS, Penicillin/Streptomycin, glutamine, non-essential amino acids, 10 mM HEPES 
and 55 uM -mercaptoethanol. Control culture medium was regular DMEM media 
(Gibco/LifeTechnologies) containing 25mM glucose, supplemented with 10% FBS, 
Penicillin/Streptomycin, glutamine, non-essential amino acids, 10 mM HEPES and 55 uM -
mercaptoethanol. For IL-2 addition experiments, 100 U/ml of recombinant human IL-2 (rhIL-2) 
was added into culture medium as indicated. RhIL-2 was obtained from the Biological Resources 
Branch (BRB), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute-
Frederick Cancer Research and Development Center (NCI-FCRDC). For primary cultures, cells 
were treated with indicated doses of 2-deoxyglucose (2DG; Sigma) for the duration of the culture. 
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For secondary stimulation, after activation for 48 h in complete medium cells were harvested and 
washed once with PBS. And cells were re-stimulated on plates coated with anti-CD3 and anti-
CD28 with indicated medium for another 48 h. Cells were treated with indicated doses of AICAR 
for 48 h or Compound C (Cayman Chemical) for last 24 h during re-stimulation. TFH conditions 
designed to increase Bcl6 expression in wild-type cells by blocking the IL-2 pathway (Oestreich 
et al. 2012; Liao et al. 2014) used IL-6 and IL-21 (50 ng/ml each (Peprotech)), plus anti-IFNγ, -IL-
2, -IL-4 and -TGF- Abs (BioXcel), and anti-CD25, -CD122 (BD Biosciences).  All neutralizing Abs 
used at 10 µg/mL each. EL4 cells were obtained from the laboratory of Dr. Mark Kaplan (Indiana 
University School of Medicine) and cultured with the indicated medium for 48 h.  
 
Human naive CD4 T cell isolation and culture. Cryopreserved human peripheral blood 
mononuclear cells (PBMCs) from unidentified healthy donors were thawed in a 37°C water bath, 
then washed twice with pre-warmed complete RPMI 1640 culture medium. Naive CD4 T cells 
were isolated using the “human naive CD4 T cell isolation kit” from Miltenyi Biotech (San Diego, 
CA) per manufacturer’s instructions. Human T cell activation beads (anti-CD3/CD28) from 
Invitrogen were added at 1:1 ratio. Cells were then split into different culture conditions at the 
density of 5x105 cells/mL, cultured in a 48-well tissue culture plate with either complete RPMI-
1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 U/ml 
penicillin/streptomycin, or glucose-free RPMI supplemented with 10% dialyzed FBS and 100 
U/ml of penicillin/streptomycin. Cells were treated with different concentrations of 2DG or AICAR 
and cultured in complete RPMI medium at 37 °C with 5% CO2 incubator for 4 days. For some 
cultures, cells were cultured in the presence of TFH-skewing human recombinant cytokine 
cocktail (1 ng/ml of IL-12, 5 ng/ml of TGF-β, and 25 ng/ml of IL-6; all from R&D Systems), 
Harvested cells were subjected to both flow cytometry and Quantitative PCR (QPCR) analysis 
for TFH cell-specific protein markers and genes respectively. 
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Flow cytometry reagents. Anti-mouse CXCR5 (2G8), GL7 (GL7), anti-BCL6 (K112-91) for 
mouse T cells and anti-TBET (4B10) were from BD Biosciences. Anti-Foxp3 (FJK-16s) and anti-
mouse CD38 were from eBioscience. Anti-mouse CD4 (GK1.5), anti-mouse B220 (RA3-6B2) 
and anti-mouse PD-1 (29F.1A12) were from Biolegend. Anti-human CD4 (OKT4), anti-human 
BCL6 (BCL-UP), anti-human CD279/PD-1 (J105), anti-human CD185/CXCR5 (MU5UBEE) and 
fixable viability dye were purchased from eBioscience.  
Cell staining for flow cytometry. After red blood cell lysis, cell suspension of total spleen cells 
were incubated with anti-mouse CD16/CD32 (BioXcell) for 5 minutes at room temperature, 
followed by surface staining for the indicated markers. For intracellular staining, after surface 
markers were stained, cells were fixed and stained with antibodies against transcription factors 
by following Foxp3 fixation kit (eBioscience) protocols. Human cells were subjected to surface 
staining with appropriate fluorochrome-conjugated antibodies for 30 min on ice. After wash, cells 
were stained with viability dye for 5 min at room temperature before fixation and permeablization 
1h at room temperature followed by the intracellular staining with APC-conjugated mouse anti-
BCL6 antibody 30 min in the dark. Cell events were collected on an LSR II flow cytometer 
(Becton Dickonson). 
ELISA. Anti-NP-KLH IgG titers in serum were measured by ELISA, as previously reported (Wu 
et al. 2015). Briefly, 96 well Nunc-Immuno plates (Sigma-Aldrich) were coated with NP-KLH 
overnight at 4o C. Wells were blocked with 1% BSA for 1 h and diluted serum was added and 
incubated at room temperature for 2 h. A peroxidase-conjugated anti-mouse IgG (Sigma-
Aldrich) was used as secondary Ab. IL-2 concentrations of medium supernatants were 
measured with mouse IL-2 ELISA kit from BD Biosciences, following the manufacturer’s 
protocol. 
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Gene expression analysis. Total RNA was prepared using the QIAGEN RNeasy Mini Kit, and 
cDNA was prepared with the Transcriptor First Strand cDNA synthesis kit (Roche), both 
following the manufacturer’s protocol. QPCR reactions were carried using TaqMan™ Fast 
Advanced Master Mix (Applied Biosystems) with commercially available specific Taqman 
primers (Life Technologies). Samples were run in duplicates and the QPCR assays were run on 
the Applied Biosystems real-time QPCR machine. Mouse samples used β-tubulin (tubb5) as the 
reference gene, and human samples used GAPDH. 
 
Statistical Analysis. All data analysis was done using Prism Graphpad software.  Unless otherwise 
stated, Student t test or ANOVA with Tukey post hoc analysis were used. Only significant 
differences (P < 0.05) are indicated in Figures. 
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FIGURE LEGENDS 
Figure 1. Induction of Bcl6 by blocking glycolysis. Naïve CD4+ T cells isolated from 
C57BL/6 mice or EL4 cells were cultured in complete (GLU+) or glucose (GLU-) deprivation 
medium. Cells were harvested for total RNA preparation or flow cytometric staining. (A) Relative 
mRNA expression was determined by quantitative RT-PCR. Bcl6 gene expression from isolated 
naïve CD4+ T cells cultured under complete or glucose deprivation medium for 72 h (n=3, mean 
± SEM).  (B) Flow cytometry histogram plot for Bcl6 and mean fluorescence intensity (MFI) of 
naïve CD4+ T cells cultured under complete or glucose deprivation medium (n=3, mean ± 
SEM).  (C) Bcl6 gene expression from EL4 cells cultured under complete or glucose deprivation 
medium for 48 hours (n=3, mean ± SEM). (D) Flow cytometry histogram plot for Bcl6 and MFI of 
EL4 cells cultured under complete or glucose deprivation medium (n=3, mean ± SEM). (E) Bcl6 
gene expression from isolated naïve CD4+ T cells cultured under complete medium with or 
without 20 mM 2DG for 72 h (n=3, mean ± SEM). *p < 0.05, ***p < 0.001 (t test). Data are 
representative of 2 independent experiments of each time point with similar results. 
Figure 2. Effects of blocking glycolysis on IL-2 and its receptor. Naïve CD4+ T cells 
isolated from C57BL/6 mice were cultured in complete (GLU+) or glucose (GLU-) deprivation 
medium for 72 h, cells were harvested for total RNA preparation and medium supernatants were 
collected for ELISA analysis. (A) Relative mRNA expression was determined by QPCR. Il2ra 
gene expression from T cells cultured under complete or glucose deprivation medium for 72 h 
(n=3, mean ± SEM). (B) Il2 gene expression from T cells cultured under complete or glucose 
deprivation medium for 72 h (n=3, mean ± SEM). (C) IL-2 concentration of medium 
supernatants harvested from complete or glucose deprivation cell culture after 72 h (n=3, mean 
± SEM). NS (not significant, p> 0.05, t test), ***p < 0.001 (t test). Data are representative of 2 
independent experiments of each time point with similar results. 
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Figure 3. Up-regulation of BCL6 by glucose deprivation is insensitive to IL-2-mediated 
inhibition of Bcl6. Naïve CD4+ T cells isolated from C57BL/6 or IL-2 KO mice were cultured 
under complete (+GLU) or glucose (GLU-) deprivation media for 72 h, with or without addition of 
100 U/ml recombinant human IL-2. Cells were harvested for total RNA preparation and relative 
mRNA expression was determined by QPCR.  (A) Bcl6 gene expression from C57BL/6 naïve 
CD4+ T cells cultured under complete or glucose deprivation medium with or without rhIL-2 
addition for 72 h (n=3, mean ± SEM). (B) Bcl6 gene expression from IL-2 KO naïve CD4+ T 
cells cultured under complete or glucose deprivation medium with or without rhIL-2 addition for 
72 h (n=3, mean ± SEM). NS (not significant, p> 0.05, two-way ANOVA), ***p < 0.001 (two-way 
ANOVA). Data are representative of 2 independent experiments of each time point with similar 
results. 
 
Figure 4. Up-regulation of BCL6 by glucose deprivation works with secondary re-
stimulation and is specific for BCL6. Naïve CD4+ T cells isolated from C57BL/6 mice were 
cultured with complete media for 48 h on anti-CD3 and anti-CD28 coated plate, cells were 
collected and washed once with PBS and cultured under complete (GLU+) or glucose (GLU-) 
deprivation medium for another 48 h on anti-CD3 and anti-CD28 coated plate. Cells were 
harvested for total RNA preparation or flow cytometric staining. (A) Relative mRNA expression 
was determined by QPCR. Bcl6 gene expression from isolated naïve CD4+ T cells cultured 
under complete or glucose deprivation medium during re-stimulation (n=3, mean ± SEM). (B) 
Pdcd1 gene expression from isolated naïve CD4+ T cells cultured under complete or glucose 
deprivation medium during re-stimulation (n=3, mean ± SEM). (C) Prdm1 gene expression from 
isolated naïve CD4+ T cells cultured under complete or glucose deprivation medium during re-
stimulation (n=3, mean ± SEM). (D) and (E) Bcl6 MFI of naïve CD4+ T cells cultured under 
complete or glucose deprivation medium during re-stimulation (n=3, mean ± SEM). (F) Tbet MFI 
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of naïve CD4+ T cells cultured under complete or glucose deprivation medium during re-
stimulation (n=3, mean ± SEM). (G) Foxp3 MFI of naïve CD4+ T cells cultured under complete 
or glucose deprivation medium during re-stimulation (n=3, mean ± SEM). *p < 0.05, ***p < 0.001 
(t test). Data are representative of two independent experiments with similar results. 
 
Figure 5. AMPK promotes BCL6 up-regulation, both in the presence or absence of 
glycolysis. (A, B) Naïve CD4+ T cells isolated from C57BL/6 mice were cultured with complete 
media for 48 h on anti-CD3 and anti-CD28 coated wells. T cells were collected and washed 
once with PBS and cultured under complete (GLU+) or glucose (GLU-) deprivation medium for 
another 48 h on anti-CD3 and anti-CD28 coated plate. Relative mRNA expression was 
determined by QPCR.  (A) Different doses of Compound C were added to cells for the last 24 h 
of re-stimulation culture. Bcl6 gene expression from isolated naïve CD4+ T cells cultured under 
complete or glucose deprivation medium with or without the addition of Compound C during re-
stimulation (n=3, mean ± SEM). (B) Different doses of AICAR were added to cells for the 48 h of 
re-stimulation culture. Bcl6 gene expression from isolated naïve CD4+ T cells cultured under 
complete medium with or without the addition of AICAR during re-stimulation. Data are 
representative of two independent experiments with similar results. (C-F) Naïve CD4+ T cells 
isolated from C57BL/6 mice were cultured with complete media for 72 h on anti-CD3 and anti-
CD28 coated wells, in medium alone or Tfh conditions (IL-6+IL-21, plus anti-IL-2, IL-2Ra, anti-
IL2Rb, anti-TGFb, anti-IL-4, anti-IFNg), with and without AICAR. Cells were harvested for RNA 
isolation and gene expression analysis by QPCR for the indicated genes. (n=3, mean ± SEM). 
*p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA). 
 
Figure 6. AICAR enhances BCL6 and TFH-dependent antibody responses in vivo. (A) 
C57BL/6 wild-type (WT) or Bcl6 cKO mice were immunized i.p. with NP-KLH or NP-KLH plus 
AICAR. Sera were harvested on day 14 post-immunization for NP-KLH-specific IgG titer 
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analysis. The X-axis shows the dilution factors. Graph shows mean ± SEM, n = 3. Data are 
representative of two independent experiments with similar results. (B-C) C57BL/6 mice were 
immunized i.p. with NP-KLH or NP-KLH plus AICAR and day 3 post immunization stained for 
percent TFH cells (B) and Bcl6 MFI of splenic TFH cells on (C). TFH cells were gated as % Foxp3- 
PD-1high CXCR5+ cells within CD4+ population. (B) n=8, mean ± SEM, from two combined 
experiments. (C) n=5, mean ± SEM. (D) Germinal center B cells were analyzed day 7 post 
immunization of C57BL/6 mice immunized i.p. with NP-KLH or NP-KLH plus AICAR. GCB cells 
are defined as B220+CD38loGL-7hi cells; n=4, mean ± SEM. *p < 0.05, ***p < 0.001 (t test).  
Figure 7. The AMPK pathway promotes TFH-like differentiation in human CD4 T cells. 
Human naïve CD4 T cells were treated with 2DG (A, B) or AICAR (C-F) at the concentrations 
indicated, in complete (GLU+) RPMI medium containing anti-CD3/CD28 activation beads, and 
cultured for 4 days. In (C, E), cells marked “Cytokines” were cultured with TFH skewing 
cytokines (IL-6, IL-12, TGF). (A, B, C, E) The expression levels of TFH genes (BCL6, CXCR5) 
were analyzed by QPCR, and normalized to the levels of GAPDH. (D, F) AICAR-treated cells 
were subjected to surface and intracellular staining with Abs to BCL6 and PD-1. Data are the 
normalized results from 3 individual T cell samples and preparations. Graphs show mean ± 
SEM, n = 3 (two-way ANOVA). *p < 0.05 (t test).  
Supplementary Figure 1. 
Naïve CD4+ T cells isolated from C57BL/6 mice were labelled with Cell Trace Violet (CTV) dye 
and cultured in complete (GLU+) or glucose (GLU-) deprivation medium for 72 hours in anti-
CD3 and anti-CD28 coated wells. Cells were harvested, fixed, stained intracellularly for Bcl6, 
then analyzed by flow cytometry. Gates show control staining without glucose, for reference. (A) 
Representative flow cytometry plots for control and Bcl6 staining. (B) Graphs of Bcl6 MFI for 
 29
total populations in (A).  (C) Graphs of CTV MFI for total populations in (A). (n=3, mean ± 
SEM). **p < 0.01, ***p < 0.001 (t test).  
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